An Outpatient Pump Shutoff Pilot Feasibility and Safety Study (PSO1)
Reduction of Nocturnal Hypoglycemia by Using Predictive Algorithms and Pump Suspension: An Outpatient Pilot Feasibility and Safety Study
The purpose of this study is to evaluate an overnight system that will turn off the insulin pump automatically if the system predicts that a low blood sugar is likely. The study system includes a combination continuous glucose monitor (CGM)/ insulin pump made by Medtronic MiniMed, Inc and a regular laptop computer that runs a computer program that predicts low blood sugar. It works by (1) measuring the glucose levels under the skin with a continuous glucose monitor, (2) using a computer program on a laptop to predict what will happen to the glucose level over the next 35-55 minutes, and (3) turning off the insulin pump when the computer program predicts that low blood sugar will occur. We have tested this system overnight in the hospital and are ready to test the system in the home environment to learn more about how well it will work and to make sure that the blood sugar does not go too high when the pump shuts off.
This study has several phases and will take about a month or a little more for a patient to complete. Patients will use the study system for about 5 days at home to show that the patient is able to use it correctly. After that, the patient will be asked to use the study system each night for an additional 3-4 weeks. During this time, the system will be active for two-thirds of the nights and not active for one-third of the nights. When the system is active and predicts that your blood sugar will become low, the insulin pump will shut off for up to 2 hours.
The study will include 2 clinical centers in the United States.
Visão geral do estudo
Descrição detalhada
Patients who meet all eligibility criteria will use the study system overnight at home for about 5 nights to demonstrate their ability to use the system and submit study data to the Coordinating Center.
Patients who successfully demonstrate their ability to use the system as described above will be eligible for the randomized trial phase. This phase consists of use of the full system as an outpatient for approximately 21 nights:
- Each night the blood glucose level will be checked with the study blood glucose (BG) meter and used to perform a calibration of the CGM. The calibration must occur no more than 90 minutes prior to activation of the system. NOTE: Patients will be instructed to calibrate the CGM per manufacturer guidelines.
- Then the system will be activated, linking the CGM and insulin pump to the computer at the bedside.
- A randomization schedule on the laptop will be used to determine whether the 'pump shut off' application will be active that night or not.
- Patients will be blinded as to whether the pump shut off is active when a session is initiated each night.
- There will not be an alarm if the pump shuts off. The CGM alarm will be set to 60 mg/dL. When a CGM alarm occurs, the patient will be asked to measure the blood glucose with a BG meter, if he/she is aware of the alarm.
- The time period for outcome assessment each night will be from the time the system is activated until it is turned off in the morning.
- Pump shut off, when it occurs, will be for up to 2 hours. Multiple instances of pump suspension can occur if there are recurrent predictions of hypoglycemia during the night.
- Patients will be asked to check blood glucose with the study BG meter, blood ketones with the study ketone meter, and urine ketones with a ketone strip each morning prior to breakfast and enter the results on the study laptop. The patient will be instructed to contact the study physician if the blood glucose or ketone readings are out of an expected range. Patients will be contacted if these morning safety values are not reported as required or are out of range.
- Patients will be asked to record all overnight carbohydrate intake on the study laptop.
- Patients will be asked to perform periodic data uploads using the study laptop. Monitoring processes will ensure that the patient is contacted if these uploads do not occur as required, or if review of an upload reveals any extreme, prolonged episodes of low or high blood glucose readings, or elevated morning blood glucose, blood ketone, or urine ketone values.
Upon completion of the study, patients as well as study clinicians will be asked to complete a questionnaire regarding use of the study system.
There will a follow-up visit after completion of 21 successful nights of study system use. A successful night of study system use is defined as use of the system for at least four hours. Phone contacts with the patients will be made once a week.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
California
-
Stanford, California, Estados Unidos, 94305
- Stanford University
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Barbara Davis Center for Childhood Diabetes
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Clinical diagnosis of type 1 diabetes and using daily insulin therapy for at least one year and an insulin infusion pump for at least 6 months
- Age >=18.0 years
- HbA1c <=8.0%
- Availability of internet access for periodic upload of study data
- Experience using the Medtronic pump and CGM and investigator is confident that subject will use CGM on a near-daily basis during the study
- Nocturnal hypoglycemia meeting the following criterion based on CGM download: during the most recent 15 nights with CGM glucose data (must be within the past 42 days), one or more nights with a sensor glucose value <=70 mg/dL.
Exclusion Criteria:
- Diabetic ketoacidosis in the past 3 months
- Hypoglycemic seizure or loss of consciousness in the past 6 months
- History of seizure disorder (except for hypoglycemic seizure)
- Coronary artery disease or heart failure
- Cystic fibrosis
- Current use of oral/inhaled glucocorticoids, beta-blockers or other medications, which in the judgment of the investigator would be a contraindication to participation in the study.
- History of ongoing renal disease (other than microalbuminuria). Creatinine level to have been obtained within the last year if subject has diabetes of >10 years duration or is over 50 years of age. If creatinine is > 1.5 mg/dL, the subject is excluded.
- History of liver disease
- Medical or psychiatric condition that in the judgment of the investigator might interfere with the completion of the protocol such as: inpatient psychiatric treatment in the past 6 months, uncontrolled adrenal disorder, and/or abuse of alcohol
- Pregnancy: A negative urine pregnancy test will be required for all premenopausal women who are not surgically sterile. Subjects who become pregnant will be discontinued from the study.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Predictive pump suspension algorithm
The study laptop will be running actively during the night and suspending the patient's pump if the algorithm predicts hypoglycemia based on the patient's continuous glucose sensor trend.
|
The study laptop will communicate to the pump causing suspension based on output from the algorithm which predicts hypoglycemia based on the continuous glucose sensor trend.
|
|
Sem intervenção: Standard of Care
The control algorithm will run passively and not recommend suspensions or resumption to the patient's pump.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Mean Morning Blood Glucose (mg/dL)- Algorithm 1
Prazo: 21 study nights
|
The primary safety outcome will be evaluated by comparing the intervention and control nights and nights with vs. without actual shut-off of the pump for several measures of hyperglycemia such as mean morning blood glucose (mg/dL). An objective was to evaluate and refine the control algorithm. The data were reviewed periodically during the study with the pre-stated goal of determining whether any changes should be made in the control algorithm. Algorithm 1 was used for the first 105 nights of the study (38 Control nights and 67 Intervention nights). The horizon prediction time of algorithm 1 was set at 70 minutes. |
21 study nights
|
|
Mean Morning Blood Glucose (mg/dL)- Algorithm 2
Prazo: 21 study nights
|
The primary safety outcome will be evaluated by comparing the intervention and control nights and nights with vs. without actual shut-off of the pump for several measures of hyperglycemia such as mean morning blood glucose (mg/dL). Algorithm 1 was modified to reduce the hypoglycemia prediction horizon from 70 minutes to 50 minutes, to suspend the pump only when the continuous glucose monitor sensor glucose value was ≤ 230 mg/dl, not suspend if there was a drop of >40 mg/dl in consecutive sensor glucose readings, and to resume insulin delivery at the first rise in sensor glucose following a suspension. There was 156 nights of study data collected (48 Control nights and 108 Intervention nights) using algorithm 2. |
21 study nights
|
|
Mean Morning Blood Glucose (mg/dL)- Algorithm 3
Prazo: 21 study nights
|
The primary safety outcome will be evaluated by comparing the intervention and control nights and nights with vs. without actual shut-off of the pump for several measures of hyperglycemia such as mean morning blood glucose (mg/dL). The hypoglycemia prediction horizon was reduced further in algorithm 3 to 30 minutes. A total of 114 study nights (37 Control nights and 77 Intervention nights) using algorithm 3. |
21 study nights
|
|
Percent Morning Blood Glucose >250 mg/dL - Algorithm 1
Prazo: 21 days
|
The primary safety outcome will be evaluated by comparing the intervention and control nights and nights with vs. without actual shut-off of the pump for several measures of hyperglycemia such as the overall percentage of mornings glucose measured with home glucose meter >250 mg/dL.
|
21 days
|
|
Percent Morning Blood Glucose >250 mg/dL - Algorithm 2
Prazo: 21 days
|
The primary safety outcome will be evaluated by comparing the intervention and control nights and nights with vs. without actual shut-off of the pump for several measures of hyperglycemia such as overall percentage of mornings glucose measured with home glucose meter >250 mg/dL.
|
21 days
|
|
Percent Morning Blood Glucose >250 mg/dL - Algorithm 3
Prazo: 21 days
|
The primary safety outcome will be evaluated by comparing the intervention and control nights and nights with vs. without actual shut-off of the pump for several measures of hyperglycemia such as overall percentage of mornings glucose measured with home glucose meter >250 mg/dL.
|
21 days
|
|
Mornings With Blood Ketones >0.6 mmol/L - Algorithm 1
Prazo: 21 days
|
The primary safety outcome will be evaluated by comparing the intervention and control nights and nights with vs. without actual shut-off of the pump for several measures of hyperglycemia such as number of mornings with blood ketones >0.6 mmol/L.
|
21 days
|
|
Mornings With Blood Ketones >0.6 mmol/L - Algorithm 2
Prazo: 21 days
|
The primary safety outcome will be evaluated by comparing the intervention and control nights and nights with vs. without actual shut-off of the pump for several measures of hyperglycemia such as number of mornings with blood ketones >0.6 mmol/L.
|
21 days
|
|
Mornings With Blood Ketones >0.6 mmol/L - Algorithm 3
Prazo: 21 days
|
The primary safety outcome will be evaluated by comparing the intervention and control nights and nights with vs. without actual shut-off of the pump for several measures of hyperglycemia such as number of mornings with blood ketones >0.6 mmol/L.
|
21 days
|
|
Mornings With Urine Ketones Characterized as Moderate or Large - Algorithm 1
Prazo: 21 days
|
The primary safety outcome will be evaluated by comparing the intervention and control nights and nights with vs. without actual shut-off of the pump for several measures of hyperglycemia such as number of mornings with urine ketones characterized as moderate or large based on measurement results of a urine dipstick test taken using Ketostix.
Moderate is considered approximately 30 - 40 mg/dL and Large >80 mg/dL.
|
21 days
|
|
Mornings With Urine Ketones Characterized as Moderate or Large - Algorithm 2
Prazo: 21 days
|
The primary safety outcome will be evaluated by comparing the intervention and control nights and nights with vs. without actual shut-off of the pump for several measures of hyperglycemia such as number of mornings with urine ketones characterized as moderate or large based on measurement results of a urine dipstick test taken using Ketostix.
Moderate is considered approximately 30 - 40 mg/dL and Large >80 mg/dL.
|
21 days
|
|
Mornings With Urine Ketones Characterized as Moderate or Large - Algorithm 3
Prazo: 21 days
|
The primary safety outcome will be evaluated by comparing the intervention and control nights and nights with vs. without actual shut-off of the pump for several measures of hyperglycemia such as number of mornings with urine ketones characterized as moderate or large based on measurement results of a urine dipstick test taken using Ketostix.
Moderate is considered approximately 30 - 40 mg/dL and Large >80 mg/dL.
|
21 days
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
Mean Sensor Glucose Overnight - Algorithm 1
Prazo: Overnight from system activation to deactivation in the morning upon awakening for 21 nights of system use
|
Overnight from system activation to deactivation in the morning upon awakening for 21 nights of system use
|
|
Mean Sensor Glucose Overnight - Algorithm 2
Prazo: Overnight from system activation to deactivation in the morning upon awakening for 21 nights of system use
|
Overnight from system activation to deactivation in the morning upon awakening for 21 nights of system use
|
|
Mean Sensor Glucose Overnight - Algorithm 3
Prazo: Overnight from system activation to deactivation in the morning upon awakening for 21 nights of system use
|
Overnight from system activation to deactivation in the morning upon awakening for 21 nights of system use
|
|
Percentage of Sensor Glucose Values 71 to 180 mg/dL - Algorithm 1
Prazo: Overnight from system activation to deactivation in the morning upon awakening for 21 nights of system use
|
Overnight from system activation to deactivation in the morning upon awakening for 21 nights of system use
|
|
Percentage of Sensor Glucose Values 71 to 180 mg/dL - Algorithm 2
Prazo: Overnight from system activation to deactivation in the morning upon awakening for 21 nights of system use
|
Overnight from system activation to deactivation in the morning upon awakening for 21 nights of system use
|
|
Percentage of Sensor Glucose Values 71 to 180 mg/dL - Algorithm 3
Prazo: Overnight from system activation to deactivation in the morning upon awakening for 21 nights of system use
|
Overnight from system activation to deactivation in the morning upon awakening for 21 nights of system use
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: John Lum, MS, Jaeb Center for Health Research
- Cadeira de estudo: Bruce A Buckingham, MD, Stanford University
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- PSO1
- R01DK085591 (Concessão/Contrato do NIH dos EUA)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .